Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) reached a new 52-week high on Monday . The company traded as high as $27.98 and last traded at $27.98, with a volume of 450 shares traded. The stock had previously closed at $27.44.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a "buy" rating and a $40.00 target price for the company. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $33.60.
Check Out Our Latest Analysis on KNSA
Kiniksa Pharmaceuticals Stock Performance
The stock has a market cap of $1.96 billion, a PE ratio of 250.82 and a beta of 0.33. The firm has a 50-day moving average price of $25.70 and a 200-day moving average price of $22.38.
Insider Activity
In related news, insider John F. Paolini sold 60,692 shares of the company's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the transaction, the insider now directly owns 52,038 shares of the company's stock, valued at approximately $1,359,232.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Eben Tessari sold 17,000 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the transaction, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now directly owns 52,038 shares of the company's stock, valued at $1,359,232.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 112,692 shares of company stock worth $2,950,315 over the last 90 days. 54.57% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 18.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 61,106 shares of the company's stock worth $1,206,000 after purchasing an additional 9,490 shares during the period. Principal Financial Group Inc. raised its position in Kiniksa Pharmaceuticals by 42.7% in the first quarter. Principal Financial Group Inc. now owns 58,991 shares of the company's stock worth $1,164,000 after acquiring an additional 17,659 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Kiniksa Pharmaceuticals by 5.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company's stock worth $413,000 after acquiring an additional 1,153 shares during the last quarter. Janney Montgomery Scott LLC grew its position in shares of Kiniksa Pharmaceuticals by 7.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 26,843 shares of the company's stock valued at $530,000 after acquiring an additional 1,940 shares during the period. Finally, Hussman Strategic Advisors Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter worth $3,107,000. 53.95% of the stock is owned by hedge funds and other institutional investors.
About Kiniksa Pharmaceuticals
(
Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
See Also
Before you consider Kiniksa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals wasn't on the list.
While Kiniksa Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
